J&J’s Acclarent, Inc., a leader in developing minimally-invasive Ear, Nose & Throat (ENT) technologies, has announced the U.S. commercial launch of TruDi, a real-time, three-dimensional (3D) navigation system for ENT procedures performed in the operating room and surgeon office.
Background
Acclarent developed TruDi in collaboration with Biosense Webster, Inc., well known on our pages as a specialist in heart rhythm disorders. TruDi leverages Biosense Webster’s advanced imaging system which uses electromagnetic technologies to help electrophysiologists navigate the beating heart by generating an accurate map, and pinpoints the exact location and orientation of catheters used during diagnostic and therapeutic procedures.
TruDi is an electromagnetic image-guided navigation system designed to offer ENT surgeons an accurate, simple and reliable option for their endoscopic sinus surgery procedures. It is intended for use during intranasal and paranasal image-guided navigation procedures for eligible patients requiring sinus surgery. TruDi enables the use of RELIEVA SPINPLUS® NAV, the first 3D navigation-enabled Balloon Sinuplasty System for the treatment of chronic sinusitis.
Acclarent’s TruDi Navigation System recently received U.S. FDA 510(k) clearance, and first cases were completed Monday, April 16th at two leading U.S. healthcare facilities.
Clinician comments
“TruDi enables precise localization of the surgical device relative to the preoperative CT scan, facilitating the surgeon’s understanding of the complex anatomy of the narrow spaces of the paranasal sinuses,” said Acclarent consultant Dr. Martin J. Citardi, Professor and Chair of the Department Otorhinolaryngology-Head and Neck Surgery at McGovern Medical School at The University of Texas Health Science Center at Houston. “The system incorporates microsensor technology, innovative tracking hardware and software tools enabling the surgeon to easily and accurately confirm instrument placement during minimally invasive sinus procedures.”
Company comments
“With the launch of TruDi, Acclarent builds on its legacy of pioneering minimally invasive treatment options for patients suffering from Chronic Sinusitis and Eustachian Tube Dysfunction,” said Shlomi Nachman, Company Group Chair of Johnson & Johnson Medical Devices Cardiovascular & Specialty Solutions. “We’re extremely proud of this advancement and the potential it has to transform ENT procedures.”
After pioneering Balloon Sinuplasty as a minimally invasive treatment option for chronic sinus sufferers, Acclarent went on to develop the first Eustachian Tube Dysfunction intervention with ACCLARENT AERA. With TruDi, Acclarent has now taken another step in advancing ENT paranasal sinus surgery with innovative 3D navigation technology.
published: April 24, 2018 in: ENT, Johnson & Johnson, Launches / Withdrawals